Johnson & Johnson Invests US$2 Billion in State-of-the-Art Biologics Facility in North Carolina, USA
Introduction:
Johnson & Johnson plans to invest US$2 billion to develop a new biologics manufacturing facility in Wilson, North Carolina, USA.
Features:
The cutting-edge 500,000-square-foot facility is designed to support biologics manufacturing and automation technologies to optimise efficiency and precision in production.
The facility will include dedicated areas for large-scale biologics processing, quality control laboratories, and warehousing, ensuring streamlined end-to-end manufacturing operations.
It is designed to produce a wide range of biologics, including monoclonal antibodies and other advanced therapies for cancer, immune-mediated, and neurological diseases.
This will continue manufacturing workflows to enhance production scalability and flexibility while maintaining strict quality standards.
Specialised automation and real-time monitoring systems will be used to ensure regulatory compliance and product consistency throughout the manufacturing process.
Construction for the expanded facility is slated to begin next year, marking a significant step in a global manufacturing growth strategy aimed at serving more patients who rely on these medicines.
Specifications:
| Name | Johnson & Johnson |
| Type | New Construction |
| Budget | US$2 billion |
| Year | 2026 |
